Global Swine Fever Vaccine Market, by Type (African Swine Fever and Classical Swine Fever), by Vaccine Type (Live-Attenuated, Chimeric (Live-attenuated or inactivated), Subunit or vector system based, and Replicon vaccine), by Distribution Channel (Public and Private), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 2,724.5 Million in 2022 and is expected to exhibit a CAGR of 5.9% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

Increased funding by various government and non-government organizations to create awareness about swine fever is expected to drive the market growth over the forecast period. For instance, in June 2022, the Michigan Alliance for Animal Agriculture (M-AAA), a partnership between the Michigan Department of Agriculture & Rural Development (MDARD), animal agriculture industry groups, and Michigan State University aimed at advancing the animal agriculture economy across the state, invested more than US$ 2.3 million for 26 new research and outreach projects in 2022. One of the projects was to assist producers with biosecurity planning to prevent and respond to disease outbreaks such as avian influenza and African swine fever. The project will support the development of an expert team to assist producers in preparedness for disease outbreaks, provide verification and tracking of biosecurity plans, and produce educational materials.

Global Swine Fever Vaccine Market – Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.

Likewise, the COVID-19 pandemic had made a negative impact on the global swine fever vaccine market, owing to the reduced access to veterinarians and problems related to transportation. For instance, according to an article published by the National Center for Biotechnology Information (NCBI) in September 2020, limited access to the veterinary dispensary or even veterinarians and also problems related to the transportation of animals to the polyclinic at the time of need led to a high level of morbidity of diseases and at times death of the animals.

Browse 27 Market Data Tables and 31 Figures spread through 156 Pages and in-depth TOC on “Global Swine Fever Vaccine Market”- Forecast to 2030, Global Swine Fever Vaccine Market, by Type (African Swine Fever and Classical Swine Fever), by Vaccine Type (Live-Attenuated, Chimeric (Live-attenuated or inactivated), Subunit or vector system based, and Replicon vaccine), by Distribution Channel (Public and Private), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/swine-fever-vaccine-market-5195

Moreover, increasing grants from governments and various research foundations to the key players in the market to develop swine fever vaccines are expected to drive the market growth over the forecast period. For instance, in April 2022, the Foundation for Food & Agriculture Research (FFAR) provided a grant of US$ 145,000 to Genvax Technologies, a startup animal vaccine company, to develop a self-amplifying messenger RNA (saRNA) vaccine for African Swine Fever (ASF) in collaboration with the United States Department of Agriculture-Agricultural Research Services-Plum Island Animal Disease Center (USDA-ARS-PIADC).

Key Takeaways of the Global Swine Fever Vaccine Market:

  • The global swine fever vaccine market is expected to exhibit a CAGR of 5.9% during the forecast period due to the increasing outbreaks and prevalence of swine fever. For instance, according to an article published by Springer Nature Limited, in September 2021, losses caused by African swine fever (ASF) outbreaks in China between August 2018 and July 2019 were estimated. According to the results, as of July 2019, there were a total of 162 ASF outbreaks in all parts of China and by mid-2019, 13,355 pigs had died due to ASF virus infection, and 1,204,281 pigs had been killed to halt the virus’s spread.
  • Among distribution channels, the private segment is estimated to hold a dominant position in the global swine fever vaccine market over the forecast period, owing to the increasing adoption of strategies such as distribution and commercialization agreements by the key market players. For instance, in October 2021, PlantForm, a biopharmaceutical company, and POSCO International, a South Korea-based trading company, signed a commercialization agreement to bring HERBAVAC, the world's first plant-based vaccine for classical swine fever (CSF), to the global markets. Under the terms of this agreement, PlantForm will have exclusive rights to import, market, sell, and distribute HERBAVAC in Canada, the U.S., Mexico, Brazil, and Argentina.
  • On the basis of region, North America is estimated to account for the largest market share in the global swine fever vaccine market over the forecast period, owing to increasing funding from government bodies to develop and produce vaccines against swine fever. For instance, in April 2022, ATCC or the American Type Culture Collection, a nonprofit organization which collects, stores, and distributes standard reference microorganisms, cell lines, and other materials for research and development, was awarded a fund of US$ 385,000 by the US Department of Agriculture (USDA) for two projects, of which one project was to create genetically modified cell lines capable of growing and producing vaccines against African Swine Fever (ASF) virus.
  • Major players operating in the global swine fever vaccine market include Merck & Co., Inc. (Merck Animal Health), Ceva, Zoetis Services LLC, Boehringer Ingelheim International GmbH, Indian Immunologicals Ltd., Bioveta, a.s., Komipharm, and EC21 Inc.

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo